XLRN - The Investment Thesis On Acceleron Pharma
Today, we take an in-depth look at a mid-cap development play that filed an important application to the FDA just under two months ago.
Company Overview:
Acceleron Pharma Inc. (XLRN) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on the development of Transforming Growth Factor-Beta (TGF-beta) protein superfamily therapeutics for the treatment of serious and rare diseases. The company was founded in 2003 and went public in 2013, raising net proceeds of $86.8 million at $15 a share. Since 2008, Acceleron has been engaged in a collaborative relationship with soon-to-be-acquired Celgene. The company